1,142
Views
1
CrossRef citations to date
0
Altmetric
Commentary

Histamine antagonists promote cancer immunosurveillance

, & ORCID Icon
Article: 2242211 | Received 21 Jul 2023, Accepted 26 Jul 2023, Published online: 05 Aug 2023

References

  • Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med. 2023;29(6):1310–3. doi: 10.1038/s41591-023-02336-1.
  • Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487–500. doi:10.1038/s41590-022-01132-2.
  • Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J, et al. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology. 2022;11(1):2096363. doi: 10.1080/2162402X.2022.2096363.
  • Zhao L, Zhang S, Kepp O, Kroemer G, Liu P. Dendritic cell transfer for cancer immunotherapy. Int Rev Cell Mol Biol. 2022;370:33–64.
  • Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology. 2019;8(11):e1638212. doi:10.1080/2162402X.2019.1638212.
  • Le Naour J, Liu P, Zhao L, Adjemian S, Sztupinszki Z, Taieb J, Mulot C, Silvin A, Dutertre CA, Ginhoux F, et al. A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. Cancer Discov. 2021;11(2):408–423. doi: 10.1158/2159-8290.CD-20-0465.
  • Zhao L, Liu P, Xie W, Zhang S, Thieme S, Zitvogel L, Kroemer G, Kepp O. A genotype-phenotype screening system using conditionally immortalized immature dendritic cells. STAR Protoc. 2021;2(3):100732. doi:10.1016/j.xpro.2021.100732.
  • Zhang S, Zhao L, Guo M, Liu P, Li S, Xie W, Tian AL, Pol JG, Chen H, Pan H, et al. Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses. J Immunother Cancer. 2023;11(7):e006785. doi: 10.1136/jitc-2023-006785.
  • Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, Yin X, Saito Y, Fan H, Li P, et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022;40(1):36–52 e9. doi: 10.1016/j.ccell.2021.11.002.
  • Verdoodt F, Dehlendorff C, Jaattela M, Strauss R, Pottegard A, Hallas J, Friis S, Kjaer SK. Antihistamines and ovarian cancer survival: nationwide cohort study and in vitro cell viability assay. J Natl Cancer Inst. 2020;112(9):964–967. doi:10.1093/jnci/djz217.
  • Fritz I, Wagner P, Olsson H. Improved survival in several cancers with use of H(1)-antihistamines desloratadine and loratadine. Transl Oncol. 2021;14(4):101029. doi:10.1016/j.tranon.2021.101029.